(IQV) IQVIA Holdings - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266C1053

Stock:

Total Rating 38

Risk 71

Buy Signal -0.68

Diagnostics & Research -14.5
Life Sciences Tools & Services -26.6

Market Cap: 28,842m
Avg Trading Vol: 481M USD

ATR: 5.25%
Peers RS (IBD): 19.35

Risk 5d forecast
Volatility	48.5%
Relative Tail Risk	-9.44%

Reward TTM
Sharpe Ratio	-0.28
Alpha	-33.20

Character TTM
Beta	0.918
Beta Downside	0.869

Drawdowns 3y
Max DD	47.12%
CAGR/Max DD	-0.18

EPS (Earnings per Share)

EPS CAGR: 9.07%
EPS Trend: -11.4%

Last SUE: 0.10
Qual. Beats: 0

Revenue

Rev. CAGR: 5.52%
Rev. Trend: 91.6%

Last SUE: 4.00
Qual. Beats: 1

Description: IQV IQVIA Holdings

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income: 1.36b TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.42 > 1.0
NWC/Revenue: -12.81% < 20% (prev -7.32%; Δ -5.49% < -1%)
CFO/TA 0.09 > 3% & CFO 2.65b > Net Income 1.36b
Net Debt (14.19b) to EBITDA (3.46b): 4.10 < 3
Current Ratio: 0.75 > 1.5 & < 3
Outstanding Shares: last quarter (171.9m) vs 12m ago -4.92% < -2%
Gross Margin: 26.28% > 18% (prev 0.33%; Δ 2595 % > 0.5%)
Asset Turnover: 57.39% > 50% (prev 57.27%; Δ 0.12% > 0%)
Interest Coverage Ratio: 3.18 > 6 (EBITDA TTM 3.46b / Interest Expense TTM 729.0m)

Altman Z'' 1.70

A: -0.07 (Total Current Assets 6.25b - Total Current Liabilities 8.34b) / Total Assets 29.94b
B: 0.25 (Retained Earnings 7.42b / Total Assets 29.94b)
C: 0.08 (EBIT TTM 2.32b / Avg Total Assets 28.42b)
D: 0.77 (Book Value of Equity 17.86b / Total Liabilities 23.31b)
Altman-Z'' Score: 1.70 = BBB

Beneish M -2.79

DSRI: 1.00 (Receivables 3.43b/3.24b, Revenue 16.31b/15.40b)
GMI: 1.26 (GM 26.28% / 33.15%)
AQI: 1.01 (AQ_t 0.76 / AQ_t-1 0.75)
SGI: 1.06 (Revenue 16.31b / 15.40b)
TATA: -0.04 (NI 1.36b - CFO 2.65b) / TA 29.94b)
Beneish M-Score: -2.79 (Cap -4..+1) = A

What is the price of IQV shares?

As of February 26, 2026, the stock is trading at USD 161.91 with a total of 3,191,903 shares traded.
Over the past week, the price has changed by -5.35%, over one month by -32.38%, over three months by -30.19% and over the past year by -15.22%.

Is IQV a buy, sell or hold?

IQVIA Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy IQV.

StrongBuy: 14
Buy: 2
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IQV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	240.3	48.4%
Analysts Target Price	240.3	48.4%

IQV Fundamental Data Overview February 21, 2026

P/E Trailing = 21.8247
P/E Forward = 12.7389
P/S = 1.7684
P/B = 4.3538
P/EG = 0.944
Revenue TTM = 16.31b USD
EBIT TTM = 2.32b USD
EBITDA TTM = 3.46b USD
Long Term Debt = 13.88b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.19b USD (from netDebt column, last quarter)
Enterprise Value = 43.04b USD (28.84b + Debt 16.17b - CCE 1.98b)
Interest Coverage Ratio = 3.18 (Ebit TTM 2.32b / Interest Expense TTM 729.0m)
EV/FCF = 17.35x (Enterprise Value 43.04b / FCF TTM 2.48b)
FCF Yield = 5.76% (FCF TTM 2.48b / Enterprise Value 43.04b)
FCF Margin = 15.21% (FCF TTM 2.48b / Revenue TTM 16.31b)
Net Margin = 8.34% (Net Income TTM 1.36b / Revenue TTM 16.31b)
Gross Margin = 26.28% ((Revenue TTM 16.31b - Cost of Revenue TTM 12.02b) / Revenue TTM)
Gross Margin QoQ = 6.69% (prev 33.49%)
Tobins Q-Ratio = 1.44 (Enterprise Value 43.04b / Total Assets 29.94b)
Interest Expense / Debt = 1.19% (Interest Expense 193.0m / Debt 16.17b)
Taxrate = 10.14% (58.0m / 572.0m)
NOPAT = 2.08b (EBIT 2.32b * (1 - 10.14%))
Current Ratio = 0.75 (Total Current Assets 6.25b / Total Current Liabilities 8.34b)
Debt / Equity = 2.49 (Debt 16.17b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 4.10 (Net Debt 14.19b / EBITDA 3.46b)
Debt / FCF = 5.72 (Net Debt 14.19b / FCF TTM 2.48b)
Total Stockholder Equity = 6.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 1.36b / Total Assets 29.94b)
RoE = 22.28% (Net Income TTM 1.36b / Total Stockholder Equity 6.10b)
RoCE = 11.61% (EBIT 2.32b / Capital Employed (Equity 6.10b + L.T.Debt 13.88b))
RoIC = 9.98% (NOPAT 2.08b / Invested Capital 20.90b)
WACC = 6.34% (E(28.84b)/V(45.02b) * Re(9.30%) + D(16.17b)/V(45.02b) * Rd(1.19%) * (1-Tc(0.10)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.42%
[DCF] Terminal Value 85.60% ; FCFF base≈2.33b ; Y1≈2.59b ; Y5≈3.38b
[DCF] Fair Price = 428.3 (EV 86.83b - Net Debt 14.19b = Equity 72.64b / Shares 169.6m; r=6.34% [WACC]; 5y FCF grow 12.75% → 2.90% )
EPS Correlation: -11.40 | EPS CAGR: 9.07% | SUE: 0.10 | # QB: 0
Revenue Correlation: 91.62 | Revenue CAGR: 5.52% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.83 | Chg7d=-0.006 | Chg30d=-0.129 | Revisions Net=-9 | Analysts=18
EPS current Year (2026-12-31): EPS=12.70 | Chg7d=+0.006 | Chg30d=-0.238 | Revisions Net=-16 | Growth EPS=+6.5% | Growth Revenue=+5.7%
EPS next Year (2027-12-31): EPS=14.07 | Chg7d=-0.003 | Chg30d=-0.253 | Revisions Net=-8 | Growth EPS=+10.8% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 9.3% - Earnings Yield 4.6%)
[Growth] Growth Spread = +2.4% (Analyst 7.1% - Implied 4.7%)

Additional Sources for IQV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle